A panel of microRNA signature as a tool for predicting survival of patients with urothelial carcinoma of the bladder

Teruo Inamoto, Hirofumi Uehara, Yukihiro Akao, Naokazu Ibuki, Kazumasa Komura, Kiyoshi Takahara, Tomoaki Takai, Taizo Uchimoto, Kenkichi Saito, Naoki Tanda, Yuki Yoshikawa, Koichiro Minami, Hajime Hirano, Hayahito Nomi, Ryuji Kato, Tetsuya Hayashi, Haruhito Azuma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction and Objectives. MicroRNA (miRNA) expression is altered in urologic malignancies, including urothelial carcinoma of the bladder (UCB). Individual miRNAs have been shown to modulate multiple signaling pathways that contribute to BC. To identify a panel of miRNA signature that can predict aggressive phenotype from normal nonaggressive counterpart using miRNA expression levels and to assess the prognostic value of this specific miRNA markers in patients with UCB. Methods. To determine candidate miRNAs as prognostic biomarkers for dividing aggressive type of UCB, miRNA expression was profiled in patients' samples with an aggressive phenotype or nonaggressive phenotype using 3D-Gene miRNA labeling kit (Toray, Japan). To create a prognostic index model, we used the panel of 9-miRNA signature based on Cancer Genome Atlas (TCGA) data portal (TCGA Data Portal (https://tcgadata.nci.nih.gov/tcga/tcgaHome2.jsp)). miRNA expression data and corresponding clinical data, including outcome and staging information of 84 UCB patients, were obtained. The Kaplan-Meier and log-rank test were performed to quantify the survival functions in two groups. Results. Deregulation of nine miRNAs (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-145-5p, hsa-miR-4324, hsa-miR-34b-5p, hsa-miR-29c-3p, hsa-miR-135a-3p, and hsa-miR-33b-3p) was determined in UCB patients with aggressive phenotype compared with nonaggressive subject. To validate the prognostic power of the nine-signature miRNAs using the TCGA dataset of bladder cancer, the survival status and tumor miRNA expression of all 84 TCGA UCB patients were ranked according to the prognostic score values. Of nine miRNAs, six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p). Patients with the high-risk miRNA signature exhibited poorer OS than patients expressing the low-risk miRNA profile (HR = 7.05, p < 0 001). Conclusions. The miRNA array identified nine dysregulated miRNAs from clinical samples. This panel of nine-miRNA signature provides predictive and prognostic value of patients with UCB.

Original languageEnglish
Article number5468672
JournalDisease Markers
Volume2018
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

MicroRNAs
Urinary Bladder
Carcinoma
Survival
Phenotype
Genes
Neoplasms
Deregulation
Atlases
Biomarkers
Urinary Bladder Neoplasms

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Inamoto, Teruo ; Uehara, Hirofumi ; Akao, Yukihiro ; Ibuki, Naokazu ; Komura, Kazumasa ; Takahara, Kiyoshi ; Takai, Tomoaki ; Uchimoto, Taizo ; Saito, Kenkichi ; Tanda, Naoki ; Yoshikawa, Yuki ; Minami, Koichiro ; Hirano, Hajime ; Nomi, Hayahito ; Kato, Ryuji ; Hayashi, Tetsuya ; Azuma, Haruhito. / A panel of microRNA signature as a tool for predicting survival of patients with urothelial carcinoma of the bladder. In: Disease Markers. 2018 ; Vol. 2018.
@article{b7ebddccf7e345d38f4f8ada0d3b193e,
title = "A panel of microRNA signature as a tool for predicting survival of patients with urothelial carcinoma of the bladder",
abstract = "Introduction and Objectives. MicroRNA (miRNA) expression is altered in urologic malignancies, including urothelial carcinoma of the bladder (UCB). Individual miRNAs have been shown to modulate multiple signaling pathways that contribute to BC. To identify a panel of miRNA signature that can predict aggressive phenotype from normal nonaggressive counterpart using miRNA expression levels and to assess the prognostic value of this specific miRNA markers in patients with UCB. Methods. To determine candidate miRNAs as prognostic biomarkers for dividing aggressive type of UCB, miRNA expression was profiled in patients' samples with an aggressive phenotype or nonaggressive phenotype using 3D-Gene miRNA labeling kit (Toray, Japan). To create a prognostic index model, we used the panel of 9-miRNA signature based on Cancer Genome Atlas (TCGA) data portal (TCGA Data Portal (https://tcgadata.nci.nih.gov/tcga/tcgaHome2.jsp)). miRNA expression data and corresponding clinical data, including outcome and staging information of 84 UCB patients, were obtained. The Kaplan-Meier and log-rank test were performed to quantify the survival functions in two groups. Results. Deregulation of nine miRNAs (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-145-5p, hsa-miR-4324, hsa-miR-34b-5p, hsa-miR-29c-3p, hsa-miR-135a-3p, and hsa-miR-33b-3p) was determined in UCB patients with aggressive phenotype compared with nonaggressive subject. To validate the prognostic power of the nine-signature miRNAs using the TCGA dataset of bladder cancer, the survival status and tumor miRNA expression of all 84 TCGA UCB patients were ranked according to the prognostic score values. Of nine miRNAs, six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p). Patients with the high-risk miRNA signature exhibited poorer OS than patients expressing the low-risk miRNA profile (HR = 7.05, p < 0 001). Conclusions. The miRNA array identified nine dysregulated miRNAs from clinical samples. This panel of nine-miRNA signature provides predictive and prognostic value of patients with UCB.",
author = "Teruo Inamoto and Hirofumi Uehara and Yukihiro Akao and Naokazu Ibuki and Kazumasa Komura and Kiyoshi Takahara and Tomoaki Takai and Taizo Uchimoto and Kenkichi Saito and Naoki Tanda and Yuki Yoshikawa and Koichiro Minami and Hajime Hirano and Hayahito Nomi and Ryuji Kato and Tetsuya Hayashi and Haruhito Azuma",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/5468672",
language = "English",
volume = "2018",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",

}

Inamoto, T, Uehara, H, Akao, Y, Ibuki, N, Komura, K, Takahara, K, Takai, T, Uchimoto, T, Saito, K, Tanda, N, Yoshikawa, Y, Minami, K, Hirano, H, Nomi, H, Kato, R, Hayashi, T & Azuma, H 2018, 'A panel of microRNA signature as a tool for predicting survival of patients with urothelial carcinoma of the bladder', Disease Markers, vol. 2018, 5468672. https://doi.org/10.1155/2018/5468672

A panel of microRNA signature as a tool for predicting survival of patients with urothelial carcinoma of the bladder. / Inamoto, Teruo; Uehara, Hirofumi; Akao, Yukihiro; Ibuki, Naokazu; Komura, Kazumasa; Takahara, Kiyoshi; Takai, Tomoaki; Uchimoto, Taizo; Saito, Kenkichi; Tanda, Naoki; Yoshikawa, Yuki; Minami, Koichiro; Hirano, Hajime; Nomi, Hayahito; Kato, Ryuji; Hayashi, Tetsuya; Azuma, Haruhito.

In: Disease Markers, Vol. 2018, 5468672, 01.01.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A panel of microRNA signature as a tool for predicting survival of patients with urothelial carcinoma of the bladder

AU - Inamoto, Teruo

AU - Uehara, Hirofumi

AU - Akao, Yukihiro

AU - Ibuki, Naokazu

AU - Komura, Kazumasa

AU - Takahara, Kiyoshi

AU - Takai, Tomoaki

AU - Uchimoto, Taizo

AU - Saito, Kenkichi

AU - Tanda, Naoki

AU - Yoshikawa, Yuki

AU - Minami, Koichiro

AU - Hirano, Hajime

AU - Nomi, Hayahito

AU - Kato, Ryuji

AU - Hayashi, Tetsuya

AU - Azuma, Haruhito

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction and Objectives. MicroRNA (miRNA) expression is altered in urologic malignancies, including urothelial carcinoma of the bladder (UCB). Individual miRNAs have been shown to modulate multiple signaling pathways that contribute to BC. To identify a panel of miRNA signature that can predict aggressive phenotype from normal nonaggressive counterpart using miRNA expression levels and to assess the prognostic value of this specific miRNA markers in patients with UCB. Methods. To determine candidate miRNAs as prognostic biomarkers for dividing aggressive type of UCB, miRNA expression was profiled in patients' samples with an aggressive phenotype or nonaggressive phenotype using 3D-Gene miRNA labeling kit (Toray, Japan). To create a prognostic index model, we used the panel of 9-miRNA signature based on Cancer Genome Atlas (TCGA) data portal (TCGA Data Portal (https://tcgadata.nci.nih.gov/tcga/tcgaHome2.jsp)). miRNA expression data and corresponding clinical data, including outcome and staging information of 84 UCB patients, were obtained. The Kaplan-Meier and log-rank test were performed to quantify the survival functions in two groups. Results. Deregulation of nine miRNAs (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-145-5p, hsa-miR-4324, hsa-miR-34b-5p, hsa-miR-29c-3p, hsa-miR-135a-3p, and hsa-miR-33b-3p) was determined in UCB patients with aggressive phenotype compared with nonaggressive subject. To validate the prognostic power of the nine-signature miRNAs using the TCGA dataset of bladder cancer, the survival status and tumor miRNA expression of all 84 TCGA UCB patients were ranked according to the prognostic score values. Of nine miRNAs, six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p). Patients with the high-risk miRNA signature exhibited poorer OS than patients expressing the low-risk miRNA profile (HR = 7.05, p < 0 001). Conclusions. The miRNA array identified nine dysregulated miRNAs from clinical samples. This panel of nine-miRNA signature provides predictive and prognostic value of patients with UCB.

AB - Introduction and Objectives. MicroRNA (miRNA) expression is altered in urologic malignancies, including urothelial carcinoma of the bladder (UCB). Individual miRNAs have been shown to modulate multiple signaling pathways that contribute to BC. To identify a panel of miRNA signature that can predict aggressive phenotype from normal nonaggressive counterpart using miRNA expression levels and to assess the prognostic value of this specific miRNA markers in patients with UCB. Methods. To determine candidate miRNAs as prognostic biomarkers for dividing aggressive type of UCB, miRNA expression was profiled in patients' samples with an aggressive phenotype or nonaggressive phenotype using 3D-Gene miRNA labeling kit (Toray, Japan). To create a prognostic index model, we used the panel of 9-miRNA signature based on Cancer Genome Atlas (TCGA) data portal (TCGA Data Portal (https://tcgadata.nci.nih.gov/tcga/tcgaHome2.jsp)). miRNA expression data and corresponding clinical data, including outcome and staging information of 84 UCB patients, were obtained. The Kaplan-Meier and log-rank test were performed to quantify the survival functions in two groups. Results. Deregulation of nine miRNAs (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-145-5p, hsa-miR-4324, hsa-miR-34b-5p, hsa-miR-29c-3p, hsa-miR-135a-3p, and hsa-miR-33b-3p) was determined in UCB patients with aggressive phenotype compared with nonaggressive subject. To validate the prognostic power of the nine-signature miRNAs using the TCGA dataset of bladder cancer, the survival status and tumor miRNA expression of all 84 TCGA UCB patients were ranked according to the prognostic score values. Of nine miRNAs, six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p). Patients with the high-risk miRNA signature exhibited poorer OS than patients expressing the low-risk miRNA profile (HR = 7.05, p < 0 001). Conclusions. The miRNA array identified nine dysregulated miRNAs from clinical samples. This panel of nine-miRNA signature provides predictive and prognostic value of patients with UCB.

UR - http://www.scopus.com/inward/record.url?scp=85055621204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055621204&partnerID=8YFLogxK

U2 - 10.1155/2018/5468672

DO - 10.1155/2018/5468672

M3 - Article

VL - 2018

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

M1 - 5468672

ER -